Clinical Trial: Comparison of the efficacy and safety of bemarituzumab combined with anlotinib induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy combined with bemarituzumab maintenance therapy in stage III unresectable NSCLC: a randomised, controlled, multicentre phase II clinical study (China)

China, Aug. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Comparison of the efficacy and safety of bemarituzumab combined with anlotinib induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy combined with bemarituzumab maintenance therapy in stage III unresectable NSCLC: a randomised, controlled, multicentre phase II clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130168

Registration Time: 2026/08/17

Type: Interventional study

Primary Sponsor: The Third Xiangya Hospital Central South University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=329892

Publ...